Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 2 Pheochromocytoma 1 Paraganglioma 1 Metastatic Castration Resistant Prostate Cancer (mCRPC) 1 Gastro-enteropancreatic neuroendocrine tumor 1 Carcinoma, Adenoid Cystic 1

Interventions

pembrolizumab 3 apatinib 3 Magnetic Resonance Spectroscopy 3 lenvatinib 2 Specimen Handling 2 Nivolumab 2 Imatinib Mesylate 2 Epirubicin 2 Cisplatin 2 Carboplatin 2 Axitinib 2 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 regorafenib 1 gallium 68 PSMA-11 1 enfortumab vedotin 1 cabozantinib 1 avelumab 1 anlotinib 1 amivantamab 1 Tretinoin 1 Sunitinib 1 Radiation 1 Pemetrexed 1 Nelfinavir 1 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1 Lutetium-177 1 Lutetium 1 Ipilimumab 1 Glutamate Carboxypeptidase II 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Adenoid Cystic × Lutetium-177 × Clear all

NCT06199453 2025-02-10

LuRM_ACC/2023

Maria Sklodowska-Curie National Research Institute of Oncology

Phase 2 Withdrawn

Carcinoma, Adenoid Cystic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡